Oncology

Back to articles

For Breast Cancer, Endocrine Therapy May Be Superior to Chemotherapy

KEY POINT

Complete endocrine blockade—achieved with goserelin (Zoladex—AstraZenece) administration for 3 years and tamoxifen (Nolvadex—AstraZeneca) therapy for 5 years—is superior to standard chemotherapy in the adjuvant treatment of premenopausal women with stage I and II breast cancer. Goserelin alone appears to be an effective alternative to chemotherapy in premenopausal patients with estrogen receptor (ER)-positive and node-positive early breast cancer.

SOURCES

Jakesz R et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20:4621–7.

Jonat W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20:4628–35.